glp-1 drugs key developments 2025 pharmaceutical companies partnerships GLP-1 Analogues Market Report, Growth and Forecast Outlook for obesity in 2025:

lecture fees from Novo Nordisk, AstraZeneca, and MSD

Zhou Y, Zhu J, Wu H, Deng Y, Ji Q

presented that patients taking GLP-1RAs (exenatide or semaglutide) were four times more likely to have increased RGC during upper endoscopy than control ( OR 4.22

Healthcare providers can address these concerns by discussing them with patients and weighing the potential benefits of GLP-1RAs therapy against the risks

With stratification by sex, the analyses yielded similar results, with a significantly higher IRR of liver (2.52), pancreatic (33.84), and prostate (2.95) cancers in men and a significantly higher IRR of gallbladder and biliary tract (12.19), pancreatic (13.49), and breast (2.16) cancers in women